Bausch+Lomb IPO Presentation Deck
Multiple levers for potential margin expansion²
Shift Surgical portfolio
to premium categories
Launch high-margin
Pharmaceutical
products
Continue to increase
scale in Vision Care
Operational
efficiencies
Adj. EBITDA
Margin¹
(% revenue)
BAUSCH+ LOMB
1.
2.
2019
enVista toric
INFUSE
Bio
true
Low to Mid 20%
2020
2021
XIPERE
LAN
ARE 2
Opportunity for
Margin Expansion
2022
Ocuvile
ADAILT NO
Ranibizumab
biosimilar
NOV03
el
2023
Adjusted EBITDA margin (non-GAAP) does not reflect stand-alone costs. See slide 2 and Appendix for more information regarding non-GAAP measures.
See Slide 2 for further information regarding forward-looking statements.
Wom
2024
DIE
FINANCIAL
PERFORMANCE
hu
Opportunity
for margin
expansion
2025
Preser We
AREDS
2026+
43View entire presentation